within Pharmacolibrary.Drugs.ATC.A;

model A16AX23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0006666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A16AX23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Leriglitazone is a selective peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It is under development primarily for the treatment of X-linked adrenoleukodystrophy (X-ALD) and other central nervous system disorders associated with neuroinflammation and metabolic dysfunction. As of June 2024, it is not yet approved for clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for oral administration in healthy adult subjects based on typical small molecule PK and limited phase 1/2 data summaries available as per press releases and clinicaltrials.gov; no peer-reviewed, citable published PK model with detailed parameters available.</p><h4>References</h4><ol><li><p>Traver, E, et al., &amp; Pizcueta, P (2024). Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 13(6) 982–993. DOI:<a href=&quot;https://doi.org/10.1002/psp4.13132&quot;>10.1002/psp4.13132</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38549500/&quot;>https://pubmed.ncbi.nlm.nih.gov/38549500</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A16AX23;
